Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorBamias, A.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorKarayannopoulou, G.en
dc.contributor.authorBobos, M.en
dc.contributor.authorAthanassiou, E.en
dc.contributor.authorKalogeras, K. T.en
dc.contributor.authorTolis, C.en
dc.contributor.authorTsekeris, P.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorVamvouka, C.en
dc.contributor.authorZaramboukas, T.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorZamboglou, N.en
dc.contributor.authorMisailidou, D.en
dc.date.accessioned2015-11-24T18:26:57Z
dc.date.available2015-11-24T18:26:57Z
dc.identifier.issn0250-7005-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/15977
dc.rightsDefault Licence-
dc.subjecthead and neck canceren
dc.subjectchemotherapyen
dc.subjectradiation therapyen
dc.subjectdocetaxelen
dc.subjectercc1en
dc.subjectsquamous-cell carcinomaen
dc.subjectgrowth-factor receptoren
dc.subjectlocally advanced headen
dc.subjectgroup phase-iien
dc.subjectimmunohistochemical evidenceen
dc.subjectchemoradiation paradigmen
dc.subjectprotein overexpressionen
dc.subjectpten expressionen
dc.subjectpoor-prognosisen
dc.subjectlung-canceren
dc.titleInduction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Necken
heal.abstractBackground: Induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) has the potential of being an ideal multi-modality approach for improving the prognosis of patients with squamous cell carcinoma of the head and neck (SSCHN). Patients and Methods: Thirty-four patients with locally advanced SCCHN were treated with 3 cycles of IC, consisting of docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) even 3 weeks, followed 3-4 weeks later by definitive radiotherapy (70 Gy) and concomitant weekly cisplatin 40 mg/m(2). Results: After a median follow-up of 27.7 months, 6-month progression-free survival (PFS), the primary study end-point, was 84%. The median PFS was 16.4 months and median overall survival 24.4 months. The majority of the patients completed 3 cycles of IC with mild to moderate toxicity. Anemia, nausea/vomiting and mucositis were the prominent toxicities during CCRT Retrospective analysis of a panel of biomarkers suggested that excision repair cross-complementation group 1 (ERCC1) protein expression was associated with shorter PFS. Conclusion: IC followed by CCRT as administered in the present study, is a feasible and well-tolerated therapeutic approach. However, its real impact on the prognosis of SCCHN patients has to be demonstrated in a randomized study comparing this treatment to CCRT alone.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondary<Go to ISI>://000263731300012-
heal.identifier.secondaryhttp://ar.iiarjournals.org/content/29/2/529.full.pdf-
heal.journalNameAnticancer Resen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2009-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιώνel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)